Market Analysis

Research and Markets examines use of bisphosphonates in treating bone loss and metastases

Published in Cancer Weekly, April 17th, 2006

Research and Markets has announced the addition of Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of Cancer to their offering.

Intravenous (IV) treatment with bisphosphonates such as pamidronate (Novartis's Aredia) and zoledronic acid (Novartis's Zometa), in conjunction with standard chemotherapy, has become the standard of care for patients with bone lesions due to multiple myeloma and for patients with solid tumors who have bone metastases. These agents are used to reduce the incidence of bone-metastasis-related exacerbations such as bone pain, fractures, and spinal cord compression.

A major new potential market segment for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry